Literature DB >> 20610814

DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.

Rita Shaknovich1, Huimin Geng, Nathalie A Johnson, Lucas Tsikitas, Leandro Cerchietti, John M Greally, Randy D Gascoyne, Olivier Elemento, Ari Melnick.   

Abstract

Expression profiling has shown 2 main and clinically distinct subtypes of diffuse large B-cell lymphomas (DLBCLs): germinal-center B cell-like (GCB) and activated B cell-like (ABC) DLBCLs. Further work has shown that these subtypes are partially characterized by distinct genetic alterations and different survival. Here, we show with the use of an assay that measures DNA methylation levels of 50,000 CpG motifs distributed among more than 14,000 promoters that these 2 DLBCL subtypes are also characterized by distinct epigenetic profiles. DNA methylation and gene expression profiling were performed on a cohort of 69 patients with DLBCL. After assigning ABC or GCB labels with a Bayesian expression classifier trained on an independent dataset, a supervised analysis identified 311 differentially methylated probe sets (263 unique genes) between ABC and GCB DLBCLs. Integrated analysis of methylation and gene expression showed a core tumor necrosis factor-α signaling pathway as the principal differentially perturbed gene network. Sixteen genes overlapped between the core ABC/GCB methylation and expression signatures and encoded important proteins such as IKZF1. This reduced gene set was an accurate predictor of ABC and GCB subtypes. Collectively, the data suggest that epigenetic patterning contributes to the ABC and GCB DLBCL phenotypes and could serve as useful biomarker.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20610814      PMCID: PMC2993635          DOI: 10.1182/blood-2010-05-285320

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  A universal framework for regulatory element discovery across all genomes and data types.

Authors:  Olivier Elemento; Noam Slonim; Saeed Tavazoie
Journal:  Mol Cell       Date:  2007-10-26       Impact factor: 17.970

2.  Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.

Authors:  B Belinda Ding; J Jessica Yu; Raymond Y-L Yu; Lourdes M Mendez; Rita Shaknovich; Yonghui Zhang; Giorgio Cattoretti; B Hilda Ye
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

3.  Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.

Authors:  J Iqbal; T C Greiner; K Patel; B J Dave; L Smith; J Ji; G Wright; W G Sanger; D L Pickering; S Jain; D E Horsman; Y Shen; K Fu; D D Weisenburger; C P Hans; E Campo; R D Gascoyne; A Rosenwald; E S Jaffe; J Delabie; L Rimsza; G Ott; H K Müller-Hermelink; J M Connors; J M Vose; T McKeithan; L M Staudt; W C Chan
Journal:  Leukemia       Date:  2007-07-12       Impact factor: 11.528

4.  An analytical pipeline for genomic representations used for cytosine methylation studies.

Authors:  Reid F Thompson; Mark Reimers; Batbayar Khulan; Mathieu Gissot; Todd A Richmond; Quan Chen; Xin Zheng; Kami Kim; John M Greally
Journal:  Bioinformatics       Date:  2008-03-18       Impact factor: 6.937

Review 5.  Diffuse large B-cell lymphoma.

Authors:  Kristin E Hunt; Kaaren K Reichard
Journal:  Arch Pathol Lab Med       Date:  2008-01       Impact factor: 5.534

Review 6.  Aggressive lymphomas.

Authors:  Georg Lenz; Louis M Staudt
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

7.  Differential DNA methylation patterns of small B-cell lymphoma subclasses with different clinical behavior.

Authors:  F B Rahmatpanah; S Carstens; J Guo; O Sjahputera; K H Taylor; D Duff; H Shi; J W Davis; S I Hooshmand; R Chitma-Matsiga; C W Caldwell
Journal:  Leukemia       Date:  2006-08-10       Impact factor: 11.528

8.  TNF-alpha as an autocrine mediator and its role in the activation of Schwann cells.

Authors:  Yongwei Qin; Chun Cheng; Haibo Wang; Xiaoyi Shao; Yongjing Gao; Aiguo Shen
Journal:  Neurochem Res       Date:  2008-01-17       Impact factor: 3.996

9.  A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation.

Authors:  J I Martín-Subero; R Ibbotson; W Klapper; L Michaux; E Callet-Bauchu; F Berger; M J Calasanz; C De Wolf-Peeters; M J Dyer; P Felman; A Gardiner; R D Gascoyne; S Gesk; L Harder; D E Horsman; M Kneba; R Küppers; A Majid; N Parry-Jones; M Ritgen; M Salido; F Solé; G Thiel; H-H Wacker; D Oscier; I Wlodarska; R Siebert
Journal:  Leukemia       Date:  2007-05-10       Impact factor: 11.528

10.  An integrative genomic and epigenomic approach for the study of transcriptional regulation.

Authors:  Maria E Figueroa; Mark Reimers; Reid F Thompson; Kenny Ye; Yushan Li; Rebecca R Selzer; Jakob Fridriksson; Elisabeth Paietta; Peter Wiernik; Roland D Green; John M Greally; Ari Melnick
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

View more
  75 in total

1.  EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis.

Authors:  Irina Velichutina; Rita Shaknovich; Huimin Geng; Nathalie A Johnson; Randy D Gascoyne; Ari M Melnick; Olivier Elemento
Journal:  Blood       Date:  2010-08-24       Impact factor: 22.113

2.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.

Authors:  Christopher J Sneeringer; Margaret Porter Scott; Kevin W Kuntz; Sarah K Knutson; Roy M Pollock; Victoria M Richon; Robert A Copeland
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

3.  New Challenges in the Management of Diffuse Large B-Cell Lymphoma.

Authors:  Christopher R Flowers; Loretta J Nastoupil; Leon Bernal-Mizrachi; Adam C Rose; Rajni Sinha
Journal:  Treat Strategies Hematol       Date:  2012-01

4.  Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes.

Authors:  Nyasha Chambwe; Matthias Kormaksson; Huimin Geng; Subhajyoti De; Franziska Michor; Nathalie A Johnson; Ryan D Morin; David W Scott; Lucy A Godley; Randy D Gascoyne; Ari Melnick; Fabien Campagne; Rita Shaknovich
Journal:  Blood       Date:  2014-01-02       Impact factor: 22.113

5.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

Authors:  Thomas Clozel; ShaoNing Yang; Rebecca L Elstrom; Wayne Tam; Peter Martin; Matthias Kormaksson; Samprit Banerjee; Aparna Vasanthakumar; Biljana Culjkovic; David W Scott; Sarah Wyman; Micheal Leser; Rita Shaknovich; Amy Chadburn; Fabrizio Tabbo; Lucy A Godley; Randy D Gascoyne; Katherine L Borden; Giorgio Inghirami; John P Leonard; Ari Melnick; Leandro Cerchietti
Journal:  Cancer Discov       Date:  2013-08-16       Impact factor: 39.397

6.  HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.

Authors:  Matko Kalac; Luigi Scotto; Enrica Marchi; Jennifer Amengual; Venkatraman E Seshan; Govind Bhagat; Netha Ulahannan; Violetta V Leshchenko; Alexis M Temkin; Samir Parekh; Benjamin Tycko; Owen A O'Connor
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

Review 7.  Epigenetics and B-cell lymphoma.

Authors:  Rita Shaknovich; Ari Melnick
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

8.  The Impact of DNA Methylation in Hematopoietic Malignancies.

Authors:  Maria Guillamot; Luisa Cimmino; Iannis Aifantis
Journal:  Trends Cancer       Date:  2016-02-01

9.  Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis.

Authors:  Meng Li; Ying-Ling Chiang; Costas A Lyssiotis; Matthew R Teater; Jun Young Hong; Hao Shen; Ling Wang; Jing Hu; Hui Jing; Zhengming Chen; Neeraj Jain; Cihangir Duy; Sucharita J Mistry; Leandro Cerchietti; Justin R Cross; Lewis C Cantley; Michael R Green; Hening Lin; Ari M Melnick
Journal:  Cancer Cell       Date:  2019-06-10       Impact factor: 31.743

Review 10.  Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions.

Authors:  James J Steinhardt; Ronald B Gartenhaus
Journal:  Clin Cancer Res       Date:  2012-06-27       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.